Biopolymer-Antigen Conjugate Vaccines for Prevention of Tularemia
ACS Infectious Diseases · 09.10.2026 · 12 (10) · 3543-3558
DOI: 10.1021/acsinfecdis.6c00694 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 15.09.2026. Verfasst von Gayathri Sam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Cell Factories and Biopolymers, Institute for Biomedicine and Glycomics, Griffith University, Brisbane, Queensland4111, Australia. Hauptthemen laut MEDLINE: Tularemia, Francisella tularensis, Antigens, Bacterial, Bacterial Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Gefördert von: DMTC, Centre for Cell Factories and Biopolymers, Griffith University, Griffith Institute for Biomedicine and Glycomics, Griffith University.
Abstract (Originalsprache)
Francisella tularensis, the causative agent of tularemia, is a facultative intracellular pathogen categorized as a tier I bioterrorism agent. The current live vaccine strain (LVS) vaccine poses safety and virulence concerns, advocating the need for a safer alternative. In this study, we demonstrated a combination of antigens FopA, Tul4, SucB, and DnaK conjugated to biopolymer particles (BPs) as a multivalent subunit vaccine that not only induces LVS and SchuS4-specific antibody titers but also confers protective immunity with differential cytokine profiles upon LVS challenge. This multivalent vaccine conferred 80% survival in mice, with antibodies of opsonizing ability and rapid recovery from weight loss. The production of these biopolymer conjugate vaccines was achieved in one step inside engineered Escherichia coli and is not only cost-effective but also leads to thermostable formulations, eliminating the need for cold-chain transport and storage. E. coli fermentation-based production avoids the need for high-containment facilities. Collectively, the FopA-BP-Tul4, SucB-BP, and Dnak-BP combined formulations hold the promise for the development of a robust subunit vaccine for the prevention of tularemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Cell Factories and Biopolymers, Institute for Biomedicine and Glycomics, Griffith University, Brisbane, Queensland4111, Australia.
- Department of Biological Sciences, University of Texas at El Paso, El Paso, Texas79968, United States.
- Menzies Health Institute Queensland, Griffith University, Gold Coast, Queensland4222, Australia.
ORCID-Profile: Charles T Spencer, Bernd H A Rehm
Förderung
- DMTC
- Centre for Cell Factories and Biopolymers, Griffith University
- Griffith Institute for Biomedicine and Glycomics, Griffith University
Zitieren
APA
Sam, G., Spencer, C. T., & Rehm, B. H. A. (2026). Biopolymer-Antigen Conjugate Vaccines for Prevention of Tularemia. ACS Infectious Diseases, 12(10), 3543-3558. https://doi.org/10.1021/acsinfecdis.6c00694
Vancouver
Sam G, Spencer CT, Rehm BHA. Biopolymer-Antigen Conjugate Vaccines for Prevention of Tularemia. ACS Infectious Diseases. 2026;12(10):3543-3558. doi:10.1021/acsinfecdis.6c00694
BibTeX
@article{Sam2026,
author = {Sam, Gayathri and Spencer, Charles T and Rehm, Bernd H A},
title = {Biopolymer-Antigen Conjugate Vaccines for Prevention of Tularemia},
journal = {ACS Infectious Diseases},
year = {2026},
volume = {12},
number = {10},
pages = {3543--3558},
doi = {10.1021/acsinfecdis.6c00694}
}
EUVIMED